Resource Library
We’ve compiled a useful collection of resources to learn more about Medrio and various aspects of managing your clinical trial in today’s complex and evolving environment.
Webinar
eCOA / ePRO•eConsent
Designing ePRO and eConsent Solutions that Participants and Sites Want
In this webinar, we will explore the powerful way that ePRO and eConsent tools, when implemented effectively, can enhance the participant experience and improve compliance while reducing the burden on site staff.
eBook
eCOA / ePRO
Facts and Misconceptions about ePRO Cost-Effectiveness
Gain guidance on misconceptions around the cost-effectiveness of electronic patient-reported outcomes (ePRO) and key points to consider when evaluating ePRO.
Success Story
CDMS / EDC•eCOA / ePRO
OncoBay Relies on Medrio ePRO and EDC for Easier, Cleaner Data
Collecting participant data securely is a critical part of running any clinical trial, whether it is decentralized, in-clinic, or somewhere in between. Medrio EDC and ePRO solutions are important assets that help CROs and sponsors do more with less.
Blog
4 Proven Participant Education Techniques to Improve Electronic Collection of Informed Consent
September 20, 2022
Participant education is a critical part of informed consent and one that is easy to improve by leveraging established patient education best practices. Medrio CEO Nicole Latimer discusses some of the most successful approaches she has seen in her career:
Webinar
RTSM
5 Supply Management Success Factors for Your Early Phase Studies
Many early phase studies rely on manual methods of managing participant randomization and the study supply chain. But increasing complexities in both study design and global supply chain necessitate more flexible, responsive solutions for early phase studies, in particular.
Blog
RTSM
How Are You Labeling Your IP? Protect Your Clinical Trial with Distinct Treatment Numbers
September 6, 2022
Does your CRO or sponsor have a policy around IP numbering in clinical trials? If not, they could be putting your clinical trial at risk.